NanoCrystal technology was developed by EDT through Elan Pharma International Limited and other Elan affiliates.
EDT, the drug delivery unit of Elan Corporation, said the NanoCrystal technology enables the formulation of poorly water soluble compounds for all routes of administration.
By applying the technology to paliperidone palmitate, healthcare professionals will be able to provide patients with consistent medication coverage for one month, potentially allowing them to improve compliance for patients with schizophrenia.
XEPLION, Janssen-Cilag’s long-acting injectable treatment for patients with schizophrenia which uses EDT’s NanoCrystal technology, was also approved by the European Commission.
EDT head and Elan executive vice president and CFO Shane Cooke said the versatility of NanoCrystal technology enabled the development of a long-acting injectable antipsychotic which is designed to help patients maintain continual treatment, reduce the likelihood of relapse and thereby potentially improve their overall quality of life.